[1] |
HAMMOND S M. An overview of microRNAs[J]. Advanced Drug Delivery Reviews, 2015, 87:3-14.
DOI
PMID
|
[2] |
SALIMINEJAD K, KHORSHID K H R, FARD S S, et al. An overview of microRNAs:biology,functions,therapeutics,and analysis methods[J]. J Cell Physiol, 2019, 234(5):5451-5465.
DOI
URL
|
[3] |
牛连杰, 张雅敏. MicroRNA在肝癌干细胞中的作用研究进展[J]. 中华肝胆外科杂志, 2018, 24(9):641-644.
|
[4] |
VERDUCI L, STRANO S, YARDEN Y, et al. The circRNA-microRNA code:emerging implications for cancer diagnosis and treatment[J]. Mol Oncol, 2019, 13(4):669-680.
DOI
URL
|
[5] |
ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36):4781-4788.
DOI
PMID
|
[6] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华肝脏病杂志, 2020, 28(2):112-128.
|
[7] |
YAYLAK B, AKGÜL B. Experimental microRNA detection methods[J]. Methods Mol Biol, 2022, 2257:33-55.
DOI
PMID
|
[8] |
OUYANG T, LIU Z, HAN Z, et al. MicroRNA detection specificity:recent advances and future perspective[J]. Anal Chem, 2019, 91(5):3179-3186.
DOI
URL
|
[9] |
Clinical and Laboratory Standards Institute. Evaluation of precision performance of quantitative measurement methods[S]. EP05-A2,CLSI, 2004.
|
[10] |
中国合格评定国家认可委员会. CNAS GL039-2019 分子诊断检验程序性能验证指南[S]. 北京: 中国合格评定国家认可委员会, 2019.
|
[11] |
National Committee for Clinical Laboratory Standards. Protocols for determination of limits of detection and limits of quantitation[S]. EP17-A,NCCLS, 2004.
|
[12] |
WS/T 416—2013 干扰实验指南[S]. 北京: 国家卫生和计划生育委员会, 2013.
|
[13] |
中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国研究型医院学会肝病专业委员会, 中华医学会肝病学分会, 等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 临床肝胆病杂志, 2021, 37(2):286-295.
|
[14] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
DOI
URL
|